Corcept Therapeutics CORT EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's EPS (basic)?
- Corcept Therapeutics (CORT) reported EPS (basic) of -$0.30 in Q1 2026.
- How has Corcept Therapeutics's EPS (basic) changed year-over-year?
- Corcept Therapeutics's EPS (basic) decreased by 257.9% year-over-year, from $0.19 to -$0.30.
- What is the long-term trend for Corcept Therapeutics's EPS (basic)?
- Over 4 years (2021 to 2025), Corcept Therapeutics's EPS (basic) has grown at a -0.5% compound annual growth rate (CAGR), from $0.97 to $0.95.
- What does EPS (basic) mean?
- The amount of net profit earned for each share of common stock currently held by investors.
- How do you interpret EPS (basic)?
- An increase indicates higher profitability per share, which is generally viewed positively by shareholders. A decrease may suggest declining earnings or an increase in the number of shares outstanding.
- How does EPS (basic) compare across companies?
- Standardized across all public companies, allowing for direct comparison of earnings power per share regardless of company size.